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Abstract  
 
Autonomic dysfunction is associated with worse outcome in many disease states. Invasive 
assessment is time consuming and rarely used in the clinical setting. However, autonomic 
data can also be derived non-invasively from beat to beat analysis of heart rate and blood 
pressure. Computer based software (power spectral analysis) permits real time analysis of 
heart rate variability in the frequency domain. This article explores the principles and practice 
of non-invasive autonomic function assessment and the consequences of changes in 
autonomic tone seen in disease states associated with increased cardiovascular disease 
morbidity and mortality.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
The autonomic nervous system (ANS) has a fundamental role in maintaining homeostasis of 
the human body through continually adjusting the functions of various organs in response to 
changing internal and external conditions. The relative reactions or changes induced by the 
ANS to maintain homeostasis is coupled with almost all physiological and therefore 
pathological conditions. 
 
The ability to reliably quantify the dynamics of the ANS is crucial for examining ANS 
dysfunction associated diseases. The activity of the ANS can be determined by measuring 
cardiac noradrenaline spill overflow to plasma using isotope dilution or by measuring muscle 
sympathetic nerve activity by microneurography. However, these methods are invasive and 
precluded from use in outpatient settings. There are non-invasive methods used to measure 
autonomic activity that include time domain, frequency domain, and non-linear phenomena, 
which are comprehensively described elsewhere [1]. Non-invasive devices can continuously 
monitor and accurately measure autonomic function by using sophisticated algorithms, such 
as power spectral analyses (PSA), housed in computer software. PSA can be derived from 
both non-parametric (fast Fourier
 
transform [FFT]) and parametric (autoregressive model) 
methods, which in the majority of instances provide comparable results. Baroreceptor reflex 
sensitivity (BRS) provides a measure of the reflex arc that adjusts heart rate (HR) in response 
to changes in blood pressure (BP). Techniques used to measure the integrity of BRS function 
include the phenylephrine bolus technique (invasive), cross spectral technique, and sequence 
technique method, which are described elsewhere [2]. The application of clinical methods 
designed to quantify ANS activity has led to an enormous understanding of human ANS 
physiology and pathophysiology in the study of disease, most notably of the cardiovascular 
system. This knowledge may be used for early clinical intervention. 
 
Cardiovascular disease (CVD), diabetes and renal dysfunction are examples of disorders that 
have been known to alter ANS balance, resulting in sympathetic predominance, which has 
been associated with an unfavourable outcome and promote the occurrence of life-threatening 
arrhythmias. In addition a reduced BRS is a marker of depressed vagal reflexes and 
associated with an increased risk of mortality. Amplified parasympathetic modulation may 
exert a protective anti-arrhythmic effect. 
 
Autonomic Assessment with Power Spectral Analysis 
 
Several investigators have studied the mechanisms involved in the cardiovascular regulation 
by means of beat-to-beat variability analysis of both HR and BP [3]. Spectral analysis 
(frequency domain) of heart rate variability (HRV) and blood pressure variability (BPV) were 
used for the first time in 1968 and 1978 respectively [3] and have subsequently become 
commonly used non-invasive methods of quantifying the autonomic modulation of the 
cardiovascular system. The main advantage of PSA of signals is the possibility to study their 
frequency specific oscillations. Therefore, not only can the degree of variability from the 
measurements be obtained, but the oscillating frequency can also be obtained. 
 
PSA involves degeneration of the haemodynamic parameters into a sum of waves 
(sinusoidal) of different amplitude and frequencies, thus the results can be displayed with the 
magnitude of variability as a function of frequency (power spectrum) [4]. Therefore, the 
power spectrum reflects the amplitude of the haemodynamic fluctuations at different 
oscillation frequencies and provides the ability to divide the sympathetic and parasympathetic 
stimulations on the heart into distinct frequencies [4], which is a technique that may provide 
clarification of the pathogenesis of disease and the role of the ANS [1].  
 
PSA of cardiovascular signals has grown considerably since the recognition that 
haemodynamic variability has become a substantial diagnostic tool for the detection of 
dysautonomia and therefore its application is of significant clinical importance. PSA 
techniques used to determine HRV and BPV usually focus on variability components with 
frequencies ranging between 0.025 and 0.50 Hz, specifically 0.04 – 0.15 Hz for low 
frequency (sympathetic cardiovascular modulation) and 0.15 – 0.4 Hz for high frequency 
(parasympathetic cardiovascular modulation), which is based on the evidence that within 
these frequency ranges, HR and BP are modulated by neural autonomic influences [5]. 
 
Autonomic Function Testing Procedures 
 
Ewing and colleagues introduced physiological stress manoeuvres for studying autonomic 
function (Ewing battery) [6]. These tests assess the integrity of parasympathetic and 
sympathetic nerve activity and have been widely accepted as a means to classify autonomic 
neuropathy in terms of its severity.  
 
 Deep Breathing 
 
With an intact parasympathetic nerve supply, HR varies during inspiration and expiration. 
The variation in HR can be studied during quiet deep breathing, with six breaths·min
-1
 the 
most reproducible method. In the semi-recumbent position, the patient breathes deeply at six 
breaths·min
-1
 (five seconds for inspiration and five seconds for expiration) and a continuous 
electrocardiogram records HR variation during the manoeuvre. The RR-intervals (RRI) 
during inspiration and expiration are calculated and the result is expressed as the mean 
difference between maximum and minimum heart rates for the manoeuvre. Normal values are 
≥15 beats·min
-1
, borderline values are 11-14 beats·min
-1 
and abnormal values are ≤10 
beats·min
-1
. Patients with diabetes with autonomic neuropathy may have a reduction in, and 
sometimes complete absence of HR variation [6].    
 
 Valsalva Maneuver  
 
To perform the Valsalva, the patient blows with an open glottis into a disposable syringe 
connected to a mercury column of a sphygmomanometer and maintains a forced expiratory 
pressure of 40 mmHg for 15-seconds. During the strain period of the Valsalva manoeuvre 
there are 4-distinct phases of HR and BP changes (figure 1). At phase 1, there is a brief 
increase in BP and a reflex fall in HR due to compression of the aorta. At phase 2, there is an 
early fall in BP with a subsequent recovery later in this phase. The BP changes are 
accompanied by an increase in HR. At phase 3, BP falls for 1-2 seconds and HR increases 
with cessation of expiration, and at phase 4, BP increases (overshoot) above baseline values 
because of delayed vasoconstriction and restored cardiac output. The BP overshoot causes a 
decrease in HR due to baroreflex control mechanisms.  
 
The Valsalva ratio is calculated by the ratio of the longest RRI post-manoeuvre, reflecting the 
bradycardic response to the BP overshoot, to the shortest RRI during the manoeuvre, 
reflecting the tachycardia during strain. Abnormal values are a ratio below 1.1.  
  
 Sustained Hand Grip 
 
The sustained handgrip test provides valuable evidence for the function of the efferent 
sympathetic nervous system. The maximum voluntary contraction is determined using a 
handgrip dynamometer and the handgrip is maintained at 30% of that maximum for 5-
minutes. During sustained muscle contraction there is an increase in BP, primarily through an 
increased HR and cardiac output with little change in peripheral vascular resistance. The 
normal response is a ≥16 mmHg increase in diastolic BP, whereas a response ≤10 mmHg is 
considered abnormal. In weak and elderly patients the sustained handgrip test can be replaced 
by the cold pressor test. 
 
 Active Orthostasis 
 
During the change from supine to standing there is a characteristic immediate increase in HR, 
which is maximal at approximately the 15
th
 beat post-standing. A relative bradycardia then 
occurs, which is maximal at approximately the 30
th
 beat post-standing. This response is 
mediated by the vagus nerve. The test is performed with the patient lying quietly on a couch 
with continuous monitoring and then asked to stand up unaided. The shortest RRI at 
approximately the 15
th
 beat and the longest RRI at approximately the 30
th
 beat post-standing 
are recorded and the characteristic HR response is expressed by the 30:15 ratio. Normal value 
is a ratio >1.04, borderline ratio 1.01-1.03 and abnormal if the ratio is <1.00. For sympathetic 
function, the result of the test is considered normal when the systolic BP decreases <10 
mmHg, borderline 11-29 mmHg and abnormal if systolic BP falls by 30 mmHg within 3-
minutes post-standing.   
 
The AFT results can be categorized into four groups: normal; early parasympathetic damage, 
where one of the three parasympathetic AFT are abnormal; definite parasympathetic damage, 
where two or more of the parasympathetic AFT are abnormal; and combined parasympathetic 
and sympathetic damage, where in addition to abnormal parasympathetic function one or 
both sympathetic tests are abnormal. Figure 2 illustrates the normal autonomic response to 
the Ewing battery of tests and figure 3 illustrates the power spectral analysis of a patient with 
normal autonomic function compared with a patient with autonomic failure.  
 
Cardiovascular Autonomic Neuropathy 
 
Autonomic dysfunction is evident in CVD conditions, advancing unfavourable prognosis in a 
number of patient groups such as in patients with hypertension, ischaemic heart disease, 
previous myocardial infarction (MI) and heart failure, which is related to premature mortality. 
 
 Hypertension 
 
The ANS plays an important role in both BP regulation and in the development of 
hypertension. Hypertension is a debilitating condition that increases the risk of cardiovascular 
morbidity and mortality and affects a large number of the world’s population. ANS 
dysfunction has been demonstrated previously in patients with systemic hypertension, where 
an increased sympathetic drive combined with decreased levels of parasympathetic 
modulation is witnessed [7]. Sympathetic hyper-activity has also been demonstrated in early 
hypertension [7], which suggests that neurohormonal dysregulation may be important in its 
aetiology, progression and consequent end-organ damage. 
Research has demonstrated that a reduced HRV is present in patients with systemic 
hypertension. In normotensive patients a lower HRV was associated with greater risk of 
developing hypertension, which is consistent with the findings that dysautonomia is present 
in the early stage of hypertension [7]. Furthermore, hypertension has been noted to impair the 
cardiac baroreflex and cause vascular alterations. A reduced BRS is a marker of depressed 
vagal reflexes and associated with an increased risk of mortality.  
 
Ischaemic Heart Disease 
 
Coronary artery disease (CAD) is a leading cause of global mortality and research has 
demonstrated that a reduced HRV is associated with the development of CAD [8] and 
predicts morbidity and mortality [9 10]. Indeed, a recent angiographic study demonstrated an 
inverse relationship with HRV and the severity of CAD [11]. Furthermore, sympathetic drive 
and parasympathetic withdrawal reflected by changes in HRV has been demonstrated in 
ambulatory human subjects with ischaemic episodes [12]. Recently, Sharma and colleagues 
[13] demonstrated different HRV responses in the presence and absence of transient 
myocardial ischaemia in patients undergoing pharmacological (dobutamine) stress 
echocardiography with matched haemodynamic and myocardial workloads. In non-ischaemic 
patients, dobutamine stress was associated with a residual predominance of parasympathetic 
over sympathetic activity. In contrast, under ischaemic conditions, there was a reverse of this 
autonomic balance with greater residual sympathetic over parasympathetic activity, and this 
response was greater as the burden of ischaemia increased. The impact of this response on 
outcome is unknown and is the subject of ongoing research.   
 
 
Myocardial Infarction 
 
Autonomic dysfunction reflected by excessive cardiac sympathetic and/or inadequate cardiac 
parasympathetic modulation is a strong and independent predictor of mortality in patients 
following a MI. In HRV analysis, the sympathetic activation is reflected by an increase in the 
low frequency oscillations with an associated increased HR. An elevated HR during 
hospitalisation and discharge in patients with acute MI has been associated with an increase 
in both short and long-term mortality. However, the use of anti-ischaemic therapy (beta-
blocker) to decrease HR was shown to reduce infarct size (by 25-30%), mortality and non-
fatal re-infarctions [14]. 
 
The dysfunction of cardiac muscle nervous innervation due to tissue infarction, resulting in 
sympathetic predominance may arise due to the interruption of the fibres that pass across the 
affected tissue [15], which results in derangement in cardiac neural activity [1]. Necrosis of 
infarct cardiac tissue and the ensuing non-contracting segments may change the geometry of 
cardiac muscle contraction, which in turn may initiate an abnormal firing of sympathetic 
fibres due to mechanical deformation of the sensory endings [16]. The markedly increased 
sympathetic activation may debilitate the activity of parasympathetic innervation (vagal 
fibres) directed to the sinus node [1]. However, an alternative explanation is that the 
responsiveness of sinus node cells to neural modulations is reduced following a MI [1]. 
 
PSA of HRV in patients surviving a MI demonstrated a reduction in total and individual 
power of spectral components. When the power of sympathetic and parasympathetic 
frequencies were calculated in normalised units an increased low frequency component and 
diminished high frequency component was observed during resting conditions and over 24-
hour electrocardiography recordings [17]. These results indicate sympathetic predominance. 
In addition, research reported a significant association between reduced HRV and increased 
rates of mortality, where patients with a low HRV had a 3.4-fold increase risk of death 
compared to patients with higher HRV [18]. Interestingly, female patients have worse 
prognosis post MI and research has indentified that women develop twice the sympathetic 
activation compared to men following an acute MI. This may be one of the mechanisms 
responsible for the known gender related differences in cardiovascular complications post MI 
[19].  
 
BRS is a marker of the capability of the ANS to reflexively increase parasympathetic activity 
and simultaneously reduce sympathetic drive in response to a sudden increase in BP. When 
reduced, the BRS is significantly associated with an increased risk of death following a MI 
and when measured together, a reduced HRV and BRS further increases the risk of mortality 
in patients following a MI [20]. 
 
In a study of 808 post MI patients, HRV was an independent and better predictor of mortality 
than mean HR [18]. Although HRV is reduced following a MI, over a period of between 6 
and 12-months HRV has been shown to improve in this population, but still remains lower 
than in healthy individuals [15]. These results suggest that markers of an imbalanced ANS 
may be useful for risk evaluation of post-MI patients [18], since the pathophysiological 
debilitation as a direct consequence of cardiac tissue infarction powerfully influences the 
activity of the ANS and therefore those patients who are at an increased risk of life 
threatening arrhythmias [21]. 
 
The pathophysiological link between a reduced HRV and increased mortality is unclear. In 
the Defibrillator in Acute Myocardial Infraction Trial (DINAMIT), patients who had a recent 
MI, reduced left ventricular ejection fraction and impaired autonomic function (as indicated 
by decreased HRV and high resting HR) did not have a survival benefit with prophylactic 
implantable cardioverter defibrillator intervention [22]. In addition, the Azimilide Post Infract 
Survival Evaluation study detailed that impaired HRV is associated with increased mortality 
but not specifically mortality from arrhythmic cause [23]. 
 
Chronic Heart Failure 
 
Chronic heart failure (CHF) is a common condition, which is difficult to manage in clinical 
practice with mortality rates exceeding 10% in patients with mild to moderate CHF, despite 
therapies that improve prognosis.  Mortality rates of more than 40% are found in New York 
Heart Association (NYHA) functional classification IV patients [24]. 
 
Major abnormalities of autonomic cardiovascular control mechanisms are associated with 
CHF, with signs of sympathetic over-activation and parasympathetic withdrawal. This change 
in autonomic activity may play an important role in both predicting survival of CHF patients 
and the pathophysiology of cardiac death [24]. 
 
The dysautonomia associated with CHF, which is often interpreted as essential in order to 
maintain haemodynamic output contributes to disease progression and is associated with poor 
prognosis. However, assessment and quantification of autonomic dysfunction through 
analysis of HRV may provide additional important prognostic value for patients with CHF, 
since it has been shown to predict clinical outcome in such patient groups [24]. 
PSA of HRV may provide clinicians with valuable information regarding deterioration of 
disease and the intervention required to preserve and/or slow disease progression in order to 
maintain functional capacity. Such interventions include pharmacological and exercise 
training, which have both been shown to modulate the autonomic nervous system, by 
reducing sympathetic drive and increasing parasympathetic output [25]. 
 
Epidemiological research has demonstrated that resting HR is an independent predictor of 
cardiovascular and all cause mortality in men and women with and without diagnosed CVD 
[26]. Pathophysiological studies indicate that a high resting HR has a direct detrimental effect 
on progression of coronary atherosclerosis, myocardial ischaemia, ventricular arrhythmia and 
left ventricular function. Cardiac resynchronization therapy (CRT) with biventricular 
pacemakers has recently been shown to improve survival in a selected group of patients with 
NYHA functional class III or IV heart failure and cardiac dyssynchrony [27]. CRT has been 
demonstrated to increase HRV [28]. A study involving 113 patients with NYHA functional 
class III or IV heart failure found that those with improved time domain measures of HRV 
within 4 weeks of initiation of cardiac resynchronisation therapy had a better outcome 
compared to those with a less pronounced response [29]. 
 
Diabetic Autonomic Neuropathy 
 
Diabetic autonomic neuropathy (DAN) is a common complication, which is positively related 
to an unfavourable outcome and carries an increased risk of morbidity and mortality. DAN 
increases with age (diabetes duration) and affects a considerable number of diabetic patients 
with large numbers presenting with symptoms. Furthermore, DAN is rarely recognised and 
poorly understood, which in part may be attributed to asymptomatic autonomic neuropathy 
and without examination may go undetected. These unsuspecting clinical features 
significantly impacts upon survival and quality of life in patients with diabetes as well as 
contributes to an increased cost of caring for the large numbers of adult diabetic patients in 
the UK. 
 
DAN is a heterogeneous disorder, which affects different parts of the nervous system and 
therefore organ systems, such as the cardiovascular system, gastrointestinal tract and others 
and presents with diverse clinical symptoms. Cardiovascular autonomic neuropathy (CAN) is 
the most researched and clinically important form of DAN, which is frequently overlooked 
and has prevalence rates of between 7.7-90% in diabetic patients [30]. However, the 
heterogeneous methodology makes it difficult to compare CAN epidemiology across 
different research studies. CAN is a frequent degenerative complication in diabetes and 
confers to an increased cardiovascular risk. Indeed, diabetic patients with impaired autonomic 
function had approximately doubled the risk of mortality when compared to non-diabetic 
patients [31]. 
 
CAN results from damage to the autonomic nerve fibres that innervate the myocardium and 
vasculature, which causes abnormalities in HR control and central and peripheral blood 
vessel dynamics. The metabolic disorders of diabetes lead to diffuse and widespread damage 
of peripheral nerves and small vessels [30]. Damage to small myelinated and unmyelinated 
nerve fibres is manifested by impairment of vagally controlled HRV with diminished 
peripheral sympathetic tone that leads to increased blood flow together with reduced thermal 
and pain sensation, which gives rise to DAN. Small nerve fibre damage can occur selectively 
or together with impairment of other sensory modalities due to the loss of large nerve fibres. 
Indeed, the ubiquitous distribution of the ANS and the fact that the vagus nerve is the longest 
of the ANS (accounting for approximately 75% of all parasympathetic activity), typically 
renders almost all organs susceptible to dysautonomia and results in DAN to be a potential 
system wide disorder [30]. 
 
Parasympathetic nervous dysfunction causes an above normal resting HR, which is possibly 
attributed to vagal impairment that results in unopposed sympathetic nervous outflow, with 
resting HR reaching up to 130 b·min
-1
. Parasympathetic nervous dysfunction occurs earlier 
than sympathetic nervous dysfunction in CAN, but advancement of disease with combined 
sympathetic and parasympathetic nervous impairment causes a slower HR. Advanced 
dysautonomia causes an apparent fixed HR, which means the determination of HR alone is 
not a reliable indication of CAN, whereas a reduction in HRV is the earliest indicator. 
 
Research has demonstrated that diabetic patients diagnosed with dysautonomia via analysis 
of HRV, have increased mortality rates of 20-27% [32] compared to 4-5% in diabetic patients 
with no dysautonomia with the rates of sudden death higher in the former group [32]. Indeed, 
HRV analysis demonstrated a reduction of both parasympathetic and sympathetic activity in 
diabetic patients [33]. Furthermore, research demonstrated that diabetic patients showed 
distinct changes in HRV and BPV with reduced BRS, which decreased from minimal to 
severe according to disease status. The sensitive methods used to collect and analyse the data 
highlighted patients with no previous evidence of dysautonomia according to conventional 
testing and demonstrated altered HRV and BPV, which may represent the early stages of 
CAN [34]. Previous studies have demonstrated that sympathetic dominance is associated with 
a higher cardiovascular mortality in diabetic patients, which may be related to cases of 
sudden death [18], despite the absence of documented pre-existing heart disease [35]. 
 
Renal Autonomic Neuropathy 
 
Renal autonomic neuropathy (RAN) is a complication that is related to a poor outcome. 
Patients presenting with chronic kidney disease (CKD) or end stage renal disease (ESRD) are 
characterised with extreme cardiovascular morbidity and mortality. Indeed, for patients aged 
between 15-30 years of age on haemodialysis, the incidence of cardiovascular death is 150 
times greater than the general population [36]. 
 
Research has demonstrated that moderate-to-severe RAN is a prominent characteristic of 
renal dysfunction and can be present in up to 63% of patients with kidney disease. The 
autonomic dysfunction involves both the sympathetic and parasympathetic nervous system 
and research has reported a parallel reduction in BRS, which is important in the overall 
integrity of autonomic control [36]. However, symptoms of RAN are often vague and non-
specific. 
 
Patients with mild to moderate renal dysfunction or ESRD, display increased levels of 
sympathetic activity compared with healthy subjects, with further evidence describing that 
the diseased kidneys themselves may be a trigger of sympathetic hyperactivity. Signals 
arising from the kidney appear to mediate sympathetic over-activity that may be the result of 
circulating uraemia-related toxins, which are present in renal dysfunction and more 
pronounced in patients with ESRD regardless of effective dialysis treatment. The circulating 
toxins may produce sustained activation of sympathetic nervous activity through stimulation 
of renal afferent signals, which has been shown to be irreversible through long-term dialysis 
[37]. Furthermore, reports have detailed that lesions may occur in both the afferent and 
efferent limbs of the ANS in conditions of chronic uraemia [37], which may also contribute 
to renal dysautonomia. 
 
A raised level of sympathetic nervous activity is now recognised as an important mechanism 
that contributes to an increased morbidity and mortality as well as the incidence of sudden 
cardiac death in RAN patients. Indeed, research has stated that high levels of circulating 
catecholamine’s adjunct with sympathetic nervous hyperactivity renders patients with renal 
dysfunction vulnerable to a series of severe cardiovascular complications, ranging from left 
ventricular hypertrophy, arterial remodelling, atherosclerosis and arrhythmias [38]. These 
adjoining diseases due to sympathetic over-activity culminates with a 92% excess risk of 
cardiovascular complications even in the absence of pre-diagnosed CVD [38]. 
 
The presence and severity of RAN does not appear to be associated with either the duration 
of renal dysfunction or dialysis treatment [37]. Therefore, the ability to use sensitive, non-
invasive and reproducible equipment that has the ability to rapidly evaluate autonomic 
nervous control in patients with renal dysfunction is advantageous for early intervention and 
prevention of premature morbidity and mortality. Indeed research observed that in patients 
with end-stage renal disease (ESRD) successful renal transplantation corrected autonomic 
function [39].  
 
 
 
 
 
 
Limitations 
 
At present, non-invasive HRV analysis requires stationary, ectopic free, recording periods. 
Therefore, populations that may benefit from HRV assessment who have 
electrocardiographic disturbances, such as frequent ectopic beats or atrial fibrillation are 
excluded.  
 
There is debate concerning the use of HRV frequency domains to represent sympathetic (low 
frequency) and parasympathetic (high frequency) cardiovascular modulation. Adhering to the 
traditional paradigm used to explain low frequency oscillations of HRV, it would be logical 
to assume that in disease states that are characterised by increased sympathetic drive, patients 
would exhibit marked increases in the low frequency component of cardiovascular 
variability. However, in patients with severe CHF, low frequency oscillations are reduced and 
in many patients absent. Indeed the greater the reduction in low frequency power the higher 
the level of sympathetic activation (measured invasively) and the greater the risk of mortality 
[40]. In addition, recent research has demonstrated that low frequency oscillations reflect 
BRS function and not cardiac sympathetic innervation [41]. Although further work is 
necessary in order to clarify and define the physiological importance of the low frequency 
distribution of HRV, overall power spectral density of HRV has continually provided 
clinically significant information, such as the association of increased mortality with reduced 
HRV in a number of disease states, including post MI, CHF, hypertension, diabetes, and renal 
disease compared to normal patients.  
 
At present there is no clear consensus for normal power spectral density of HRV values for 
male and females as well as different ethic groups. Clarifying this may provide clinicians 
with information on disease progression and therefore a therapeutic target to improve HRV 
via interventions such as pharmacological optimisation and exercise training.  
 
Summary 
 
Traditional autonomic function testing still remains the foundation in the clinical evaluation 
of patients with suspected dysautonomia. However, autonomic data can also be derived non-
invasively from beat to beat analysis of HR and BP. Computer based software (power 
spectral analysis) permits real time analysis of HRV in the frequency domain. Detection of 
autonomic dysfunction by this technique allows identification of high-risk patients who may 
benefit from earlier intervention. It may be suggested that patients who exhibit autonomic 
dysfunction are candidates for closer surveillance, which may include early coronary 
revascularisation and/or more aggressive pharmacological and/or device therapy to protect 
against premature mortality.   
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Figure Legends 
 
Figure 1. The 4-phases of normal heart rate and blood pressure changes induced by the 
Valsalva manoeuvre. 
 
Figure 2. Normal autonomic responses to the Ewing battery of tests. Analysis of the heart 
rate response to deep breathing (6-breaths⋅min
-1
), Valsalva manoeuvre, and the immediate 
response to standing assess the integrity of parasympathetic function and the analysis of the 
blood pressure response to standing and sustained hand grip reflect sympathetic function. 
 
Figure 3. Power spectral analysis of normal autonomic function compared with autonomic 
failure. In autonomic failure there is a marked preponderance of low frequency component 
activity suggesting increasing dominance of sympathetic over parasympathetic efferent 
activity. 
 
